-
Je něco špatně v tomto záznamu ?
Mechanical circulatory support in ventricular arrhythmias
G. Tavazzi, V. Dammassa, CNJ. Colombo, E. Arbustini, T. Castelein, M. Balik, C. Vandenbriele
Status neindexováno Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články, přehledy
NLK
Directory of Open Access Journals
od 2014
PubMed Central
od 2014
Europe PubMed Central
od 2014
Open Access Digital Library
od 2014-01-01
Open Access Digital Library
od 2014-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2014
PubMed
36304552
DOI
10.3389/fcvm.2022.987008
Knihovny.cz E-zdroje
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
In atrial and ventricular tachyarrhythmias, reduced time for ventricular filling and loss of atrial contribution lead to a significant reduction in cardiac output, resulting in cardiogenic shock. This may also occur during catheter ablation in 11% of overall procedures and is associated with increased mortality. Managing cardiogenic shock and (supra) ventricular arrhythmias is particularly challenging. Inotropic support may exacerbate tachyarrhythmias or accelerate heart rate; antiarrhythmic drugs often come with negative inotropic effects, and electrical reconversions may risk worsening circulatory failure or even cardiac arrest. The drop in native cardiac output during an arrhythmic storm can be partly covered by the insertion of percutaneous mechanical circulatory support (MCS) devices guaranteeing end-organ perfusion. This provides physicians a time window of stability to investigate the underlying cause of arrhythmia and allow proper therapeutic interventions (e.g., percutaneous coronary intervention and catheter ablation). Temporary MCS can be used in the case of overt hemodynamic decompensation or as a "preemptive strategy" to avoid circulatory instability during interventional cardiology procedures in high-risk patients. Despite the increasing use of MCS in cardiogenic shock and during catheter ablation procedures, the recommendation level is still low, considering the lack of large observational studies and randomized clinical trials. Therefore, the evidence on the timing and the kinds of MCS devices has also scarcely been investigated. In the current review, we discuss the available evidence in the literature and gaps in knowledge on the use of MCS devices in the setting of ventricular arrhythmias and arrhythmic storms, including a specific focus on pathophysiology and related therapies.
Adult Intensive Care Unit Royal Brompton Hospital London United Kingdom
Cardiovascular Center Onze Lieve Vrouwziekenhuis Hospital Aalst Belgium
Centre for Inherited Cardiovascular Diseases Fondazione IRCCS Policlinico San Matteo Pavia Italy
Department of Cardiovascular Diseases University Hospitals Leuven Leuven Belgium
Department of Cardiovascular Sciences KU Leuven Leuven Belgium
Department of Clinical Surgical Diagnostic and Paediatric Sciences University of Pavia Pavia Italy
PhD in Experimental Medicine University of Pavia Pavia Italy
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22031566
- 003
- CZ-PrNML
- 005
- 20230127131224.0
- 007
- ta
- 008
- 230119s2022 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3389/fcvm.2022.987008 $2 doi
- 035 __
- $a (PubMed)36304552
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Tavazzi, Guido $u Department of Clinical, Surgical, Diagnostic and Paediatric Sciences, University of Pavia, Pavia, Italy $u Department of Anaesthesia, Intensive Care and Pain Therapy, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
- 245 10
- $a Mechanical circulatory support in ventricular arrhythmias / $c G. Tavazzi, V. Dammassa, CNJ. Colombo, E. Arbustini, T. Castelein, M. Balik, C. Vandenbriele
- 520 9_
- $a In atrial and ventricular tachyarrhythmias, reduced time for ventricular filling and loss of atrial contribution lead to a significant reduction in cardiac output, resulting in cardiogenic shock. This may also occur during catheter ablation in 11% of overall procedures and is associated with increased mortality. Managing cardiogenic shock and (supra) ventricular arrhythmias is particularly challenging. Inotropic support may exacerbate tachyarrhythmias or accelerate heart rate; antiarrhythmic drugs often come with negative inotropic effects, and electrical reconversions may risk worsening circulatory failure or even cardiac arrest. The drop in native cardiac output during an arrhythmic storm can be partly covered by the insertion of percutaneous mechanical circulatory support (MCS) devices guaranteeing end-organ perfusion. This provides physicians a time window of stability to investigate the underlying cause of arrhythmia and allow proper therapeutic interventions (e.g., percutaneous coronary intervention and catheter ablation). Temporary MCS can be used in the case of overt hemodynamic decompensation or as a "preemptive strategy" to avoid circulatory instability during interventional cardiology procedures in high-risk patients. Despite the increasing use of MCS in cardiogenic shock and during catheter ablation procedures, the recommendation level is still low, considering the lack of large observational studies and randomized clinical trials. Therefore, the evidence on the timing and the kinds of MCS devices has also scarcely been investigated. In the current review, we discuss the available evidence in the literature and gaps in knowledge on the use of MCS devices in the setting of ventricular arrhythmias and arrhythmic storms, including a specific focus on pathophysiology and related therapies.
- 590 __
- $a NEINDEXOVÁNO
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Dammassa, Valentino $u PhD in Experimental Medicine, University of Pavia, Pavia, Italy $u Adult Intensive Care Unit, Royal Brompton Hospital, London, United Kingdom
- 700 1_
- $a Colombo, Costanza Natalia Julia $u Department of Anaesthesia, Intensive Care and Pain Therapy, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
- 700 1_
- $a Arbustini, Eloisa $u Centre for Inherited Cardiovascular Diseases, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
- 700 1_
- $a Castelein, Thomas $u Cardiovascular Center, Onze-Lieve-Vrouwziekenhuis Hospital, Aalst, Belgium
- 700 1_
- $a Balik, Martin $u Department of Anesthesiology and Intensive Care, First Medical Faculty and General University Hospital, Charles University in Prague, Prague, Czechia
- 700 1_
- $a Vandenbriele, Christophe $u Adult Intensive Care Unit, Royal Brompton Hospital, London, United Kingdom $u Department of Cardiovascular Diseases, University Hospitals Leuven, Leuven, Belgium $u Department of Cardiovascular Sciences, KU Leuven, Leuven, Belgium
- 773 0_
- $w MED00198704 $t Frontiers in cardiovascular medicine $x 2297-055X $g Roč. 9, č. - (2022), s. 987008
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36304552 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230119 $b ABA008
- 991 __
- $a 20230127131216 $b ABA008
- 999 __
- $a ok $b bmc $g 1889551 $s 1182899
- BAS __
- $a 3
- BAS __
- $a PreBMC-PubMed-not-MEDLINE
- BMC __
- $a 2022 $b 9 $c - $d 987008 $e 20221011 $i 2297-055X $m Frontiers in cardiovascular medicine $n Front Cardiovasc Med $x MED00198704
- LZP __
- $a Pubmed-20230119